Overview of Dr. Pro
Dr. Barbara Pro is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Northwestern Memorial Hospital. She received her medical degree from Sapienza University of Rome and has been in practice 29 years. She is one of 102 doctors at Northwestern Memorial Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She also speaks multiple languages, including Italian and Spanish. She has more than 100 publications and over 500 citings.
Office
161 Fort Washington Avenue
New York, NY 10032- Is this information wrong?
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1994 - 1997
Sapienza University of RomeClass of 1988
Certifications & Licensure
NY State Medical License 2022 - 2025
IL State Medical License 2015 - 2023
PA State Medical License 2010 - 2016
TX State Medical License 1999 - 2012
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013
Clinical Trials
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
- Join now to see all
Publications & Presentations
PubMed
- A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.Karmali, R., Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Kl...> ;Blood Advances. 2024 Apr 9
- Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-...Brian Estrella, Mark M Francescone, Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, Seda Tolu, Ahmed Sawas, Jennifer K Lue, Barbara Pro, Jennifer E Amengual> ;Leukemia & Lymphoma. 2024 Mar 22
- Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
- Join now to see all
Journal Articles
- Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin LymphomaPeter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
- Hemophagocytic Lymphohistiocytosis in Cutaneous T-cell LymphomaJaehyuk Choi, Linda M Serrano, Jason B Kaplan, Barbara Pro, Joan Guitart, JAMA
Abstracts/Posters
- Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD EvaluationBarbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...Barbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ LymphomasBarbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.2019 ASCO Annual Meeting - 6/1/2019
- A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Lymphoma Research Foundation's 2019 Swirl: Chicago Raises More Than $130,000June 5th, 2019- Lymphoma Research Foundation to Host Annual Wine Tasting Fundraising Event at the Casino in Chicago, ILMay 1st, 2019
New Therapy for Rare LymphomaAugust 30th, 2018- Join now to see all
Professional Memberships
- Member
Other Languages
- Italian, Spanish
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
Northwestern Memorial HospitalChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
